MedTrace Logo

Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

NCT00839007 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2010-09-17

No results posted yet for this study

Summary

The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.

Conditions

  • Acute Decompensated Heart Failure

Interventions

DRUG

CD-NP

Infusion of CD-NP at one of up to 6 doses or placebo

Sponsors & Collaborators

  • Nile Therapeutics

    lead INDUSTRY

Principal Investigators

  • Hsiao Lieu, MD · Nile Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-06-30
Completion
2010-07-31

Countries

  • United States
  • Germany
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00839007 on ClinicalTrials.gov